Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New biologic for breast cancer receives advisory committee approval

Sep. 3, 1998

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Sep. 2, 1998

Medarex receives milestone payment from Merck KGaA

Sep. 2, 1998

Techniclone advancing development of Tumor Necrosis Therapy into phase II

Sep. 2, 1998

Pivotal clinical trial data for rituximab published

Aug. 28, 1998

Imutec receives patent protection for Virulizin in Canada

Aug. 24, 1998

Available from NIH: immunotoxin for the treatment of ovarian cancer and mesotheliomas

Aug. 20, 1998

BLP25 cancer vaccine enters phase I testing in patients with NSCLC

Aug. 19, 1998

Canadian patent covers Jenner's cancer vaccine

Aug. 13, 1998

Avax to begin pivotal trial with M-Vax in melanoma patients

July 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...